RxDoctor Payments Data

Joseph Thibodeau, MD

Cardiovascular Disease · Omaha, NENPI 1316973381

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $50,858 of the $75,076 with a category attached, or 67.7%. 44 manufacturers reported payments, led by AstraZeneca at 43.0% of the total. Reporting peaked in 2019 at $25,453 and has fallen 86.7% since, to $3,383 in 2025. Among cardiovascular disease clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$75,076in general payments, 2019–2025

Across 709 payments — averaging $105.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$32K
  • Novartis$23K
  • Medtronic$8K
  • Boston Scientific$1K
  • Pfizer$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $7K from 38 others
$176,232in research payments, 2019–2025

Across 339 payments — averaging $519.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim Pharma GmbH & Co.kg$71K
  • Novo Nordisk AS$69K
  • Boehringer Ingelheim International GmbH$36K

What the payments were for

  • Speaking & faculty fees$50,85868%
  • Travel & lodging$3,2284%
  • Food & beverage$20,85928%
  • Education$1300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,076 in reported general payments places this provider in the 90th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$256,835
Medicare patients
2,548
Services billed
6,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban383$418,199
FarxigaDapagliflozin Propanediol101$124,347
EntrestoSacubitril/Valsartan101$121,145
XareltoRivaroxaban82$83,663
JardianceEmpagliflozin45$48,605
Repatha SureclickEvolocumab52$37,258
VascepaIcosapent Ethyl23$20,047
Praluent PenAlirocumab25$14,329
BrilintaTicagrelor12$8,837
Icosapent Ethyl12$7,464
Dabigatran EtexilateDabigatran Etexilate Mesylate16$7,052
Ranolazine ErRanolazine37$4,769
Metoprolol Succinate363$3,758
Atorvastatin Calcium448$3,328
Ezetimibe138$2,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,226$418,199383 claims
AstraZenecaFarxiga, Brilinta$32,253$133,185113 claims
NovartisEntresto$23,424$121,145101 claims
Johnson & JohnsonXarelto$231$83,66382 claims
Boehringer IngelheimJardiance$869$48,60545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 97 cardiovascular disease providers in Nebraska.

Other cardiovascular disease in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →